Gene therapy is the use of genetic material or gene-editing tools to treat or prevent disease by changing how cells function. The decade’s most surprising breakthroughs have been less about a single universal cure than about treatments reaching patients with previously difficult-to-treat conditions: personalized gene editing for a baby with a rare metabolic disorder, gene therapies that can prevent severe sickle-cell crises, and early evidence that editing immune cells may help some people with autoimmune disease. These advances build on a rapidly expanding field: the U.S. Food and Drug Administration approved the first CRISPR-based therapy in 2023, and by 2024 the agency had approved multiple gene therapies for inherited disorders and blood cancers. The breakthroughs are significant, but they come with limits—high costs, demanding treatment procedures, uncertain long-term durability, and uneven access.
Gene therapy’s unexpected breakthrough: precision editing in a single patient
Gene therapy is an umbrella term, not one technique. The U.S. National Human Genome Research Institute describes gene therapy as a way to treat disease by modifying a person’s cells, including by replacing, inactivating, or introducing genetic material. Gene editing is a related approach that makes targeted changes to DNA; it is one form of genetic medicine, alongside treatments that add a functioning gene without editing the original DNA.
One unexpected development was the speed with which researchers designed a bespoke CRISPR treatment for a single infant. In 2025, clinicians reported treating an infant with severe carbamoyl phosphate synthetase 1 deficiency, a rare inherited metabolic disorder. The team designed a patient-specific base-editing medicine aimed at the child’s particular mutation, manufactured it, and administered it in infancy. The report in the New England Journal of Medicine described early signs of benefit, including the ability to increase dietary protein and reduce reliance on some supportive measures. This was an important proof of feasibility—not evidence that individualized gene-editing treatments are already routine or that the child is cured.
Personalized base editing
Base editing is a gene-editing method that changes one DNA letter into another without making the double-strand break used by conventional CRISPR-Cas9. In the infant’s case, researchers tailored the guide and editing system to a specific disease-causing variant. The case demonstrated how genomic diagnosis, computational design, manufacturing, and specialist care could be coordinated quickly for a single patient. It also exposed major hurdles: each custom treatment requires careful safety review, a delivery system that reaches the right cells, and follow-up long enough to detect unintended effects.
Why a one-patient treatment matters
A bespoke therapy could be especially valuable for ultra-rare diseases, where a mutation may affect only a handful of people and a conventional commercial drug may not be economically viable. But a successful case does not establish a general approval pathway, predictable manufacturing cost, or equal access. Researchers and regulators will need ways to assess individualized products efficiently while preserving evidence of safety and effectiveness. For now, the breakthrough is best understood as a demonstration of what precision medicine might make possible.
Gene therapy’s established leap: treating inherited blood disorders
The strongest clinical advance of the decade has been the move from experimental gene transfer to approved treatments for serious blood disorders. In December 2023, the FDA approved Casgevy, the first U.S.-approved therapy using CRISPR-Cas9, for certain patients aged 12 years and older with sickle-cell disease. The agency also approved Lyfgenia, a gene-addition therapy for sickle-cell disease. In 2024, it approved two gene therapies for transfusion-dependent beta thalassemia: Casgevy and Zynteglo.
CRISPR therapy for sickle-cell disease
Casgevy edits a patient’s blood-forming stem cells outside the body. The treatment disrupts a regulatory region of the BCL11A gene in those cells, increasing fetal hemoglobin, which can reduce the tendency of red blood cells to sickle. The cells are then returned to the patient after high-dose chemotherapy clears space in the bone marrow. In the pivotal study cited by the FDA, 29 of 31 evaluable patients—about 93.5%—had no severe vaso-occlusive crisis for at least 12 consecutive months during the specified follow-up period. That is a striking result, but it does not mean every treated patient will have the same outcome or that the treatment eliminates all sickle-cell complications.
Gene addition and beta thalassemia
Unlike Casgevy, Zynteglo uses a lentiviral vector to add a working beta-globin gene to a patient’s stem cells. In FDA-reviewed clinical data, 32 of 36 evaluable patients with transfusion-dependent beta thalassemia achieved transfusion independence for at least 12 months, approximately 89%. Casgevy also received U.S. approval for eligible patients with transfusion-dependent beta thalassemia. These examples show two distinct strategies—editing gene regulation and adding a gene—being used to address related blood diseases.
The treatment pathway remains intensive. Patients undergo stem-cell collection, conditioning chemotherapy, hospitalization, and monitoring for complications. The therapies carry important risks, and long-term follow-up is essential because the edited or modified stem cells may persist for decades. Their list prices also run into the millions of dollars per treatment, before considering the broader costs of evaluation, hospitalization, and follow-up. Approval is therefore a landmark in what medicine can do, not proof that treatment is easy to obtain.
Gene therapy’s surprising expansion: immune cells and autoimmune disease
Gene-modified immune cells were first developed mainly as cancer treatments, but researchers are now exploring whether they can reset dysfunctional immunity in autoimmune disease. The approach uses a patient’s T cells, modifies them to recognize a target, and returns them to the body. In cancer, CAR T cells are engineered to attack malignant cells. In some autoimmune studies, the goal is different: eliminate disease-driving immune cells or create a durable immune reset.
CAR T-cell therapy as an autoimmune research strategy
Small early studies and case reports have described CAR T-cell treatment in severe autoimmune conditions, including systemic lupus erythematosus. A 2024 report in the New England Journal of Medicine followed five patients with refractory lupus treated with CD19-directed CAR T cells; the patients achieved remission during the reported follow-up. Such findings are scientifically notable because they suggest that deeply clearing certain B cells might interrupt disease activity. However, five patients cannot establish comparative effectiveness, long-term safety, or the likelihood of relapse. Larger controlled trials are needed before this can be considered established autoimmune care.
The promise and risks of immune reset
A potential advantage is that a finite course of cell therapy might produce a prolonged response, unlike medicines that must be taken continuously. The risks are substantial: CAR T-cell therapy can cause cytokine release syndrome, neurological toxicity, infections, and prolonged depletion of normal B cells. Manufacturing is complex, and the treatment requires specialist centers. For autoimmune disease, investigators must also determine whether the benefits justify these risks when established therapies are available.
Gene therapy’s emerging frontier: in-body editing and common diseases
Most approved gene therapies modify cells outside the body, then return them to the patient. In vivo gene editing instead delivers editing tools directly into the body, potentially making treatment less dependent on harvesting and transplanting cells. This approach could broaden access if it proves safe, effective, and scalable—but delivery to the correct tissue remains a central scientific challenge.
In vivo editing for inherited conditions
Early clinical research has tested lipid nanoparticles and viral vectors to carry editing instructions to organs such as the liver. In a 2021 New England Journal of Medicine study, an experimental CRISPR treatment for transthyretin amyloidosis reduced the disease-related protein in blood; a follow-up report in 2024 described sustained reductions after a single infusion in the small group studied. These results show that systemic delivery and durable biological effects may be possible. They do not yet establish a broadly available cure, and the small trial populations make continued safety monitoring essential.
A potential role in cardiovascular disease
Researchers are also investigating one-time gene-editing treatments aimed at lowering LDL cholesterol by altering genes such as PCSK9. Because cardiovascular disease affects far more people than most rare genetic disorders, this work could have major public-health implications if clinical trials demonstrate durable reductions in heart attacks and strokes. As of the evidence cited here, such approaches remain investigational; changes in a cholesterol biomarker are not a substitute for proven evidence of fewer clinical events or a complete accounting of long-term risks.
Gene therapy’s constraints: durability, safety, cost, and access
The rapid progress can obscure a basic distinction: a biological effect is not the same as a proven long-term cure. Gene therapies may involve irreversible changes, and some risks—such as off-target editing, immune reactions, or late effects—can take years to understand. The FDA requires long-term follow-up for some gene therapies, with monitoring periods that can extend to 15 years depending on the product and risk.
- Durability: Researchers must establish whether benefits persist and whether treated cells remain healthy over time.
- Safety: Studies track immune responses, unintended genetic changes, and complications related to conditioning or cell infusion.
- Access: Specialized centers, complex manufacturing, travel, insurance decisions, and multimillion-dollar prices can limit who receives treatment.
- Evidence: Many rare-disease trials enroll small numbers of people, making careful interpretation and post-approval monitoring especially important.
The World Health Organization has emphasized that human genome editing raises scientific, ethical, and governance questions, particularly when changes could be inherited by future generations. The clinical treatments described here are somatic therapies, intended to affect the treated person rather than their reproductive cells. Even so, equitable access, transparent oversight, and long-term patient follow-up remain central responsibilities.
Conclusion: gene therapy’s breakthroughs are real, but not simple
This decade’s unexpected gene therapy advances range from a custom base-editing treatment designed for one infant to FDA-approved CRISPR and gene-addition therapies for inherited blood disorders. Early CAR T-cell research suggests a possible new direction for severe autoimmune disease, while in vivo editing is testing whether genetic medicines can reach organs directly and eventually address conditions affecting much larger populations. The evidence varies: some therapies have regulatory approval and pivotal trial data; others remain early experiments.
The next step is to pair innovation with rigorous follow-up, accessible treatment pathways, and realistic communication about uncertainty. Patients and families considering a gene therapy should discuss eligibility, alternatives, risks, treatment logistics, cost, and follow-up with qualified specialists, and check current regulatory information from the FDA and relevant clinical-trial registries.
Sources: U.S. National Human Genome Research Institute, Gene Therapy, https://www.genome.gov/genetics-glossary/Gene-Therapy; U.S. Food and Drug Administration, FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease, https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease; U.S. Food and Drug Administration, FDA Approves First Gene Therapy to Treat Patients with Transfusion-Dependent Beta-Thalassemia, https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-patients-transfusion-dependent-beta-thalassemia; Frangoul et al., CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia, New England Journal of Medicine, https://www.nejm.org/doi/full/10.1056/NEJMoa2031054; Locatelli et al., Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia, New England Journal of Medicine, https://www.nejm.org/doi/full/10.1056/NEJMoa2113206; Musunuru et al., In Vivo CRISPR-Cas9 Gene Editing for Transthyretin Amyloidosis, New England Journal of Medicine, https://www.nejm.org/doi/full/10.1056/NEJMoa2107454; Gillmore et al., CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis, New England Journal of Medicine, https://www.nejm.org/doi/full/10.1056/NEJMoa2107454; Mackensen et al., Anti-CD19 CAR T Cell Therapy for Refractory Systemic Lupus Erythematosus, New England Journal of Medicine, https://www.nejm.org/doi/full/10.1056/NEJMoa2303181; U.S. Food and Drug Administration, Long Term Follow-up After Administration of Human Gene Therapy Products, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/long-term-follow-after-administration-human-gene-therapy-products; World Health Organization, Human Genome Editing: Recommendations, https://www.who.int/publications/i/item/9789240030381; New England Journal of Medicine, Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease, https://www.nejm.org/doi/full/10.1056/NEJMoa2500844.
